Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer

a systematic review and meta-analysis

Roberto Iacovelli, Cora N. Sternberg, Camillo Porta, Elena Verzoni, Filippo de Braud, Bernard Escudier, Giuseppe Procopio

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Despite the improvement in progression-free survival and response rates, none of the five anti- VEGF/VEGFR agents used for treatment of metastatic renal cell carcinoma (mRCC) reported a significant increase in patients' survival. This analysis aims to investigate their effect on overall survival (OS), performing a meta-analysis of the available studies. MEDLINE/PubMed and the Cochrane Library were searched for randomised phase III trials that compared anti-VEGF/VEGFR agents with controls as upfront treatment for mRCC. The search was restricted to phase III trials, and data extraction was conducted according to the PRISMA statement. Five randomised phase III trials were included for a total of 3,469 patients; among these, 1,801 received anti-VEGF/VEGFR agents and 1,668 were treated with a placebo or interferon-α. In the overall population, the reduction in the risk of death was 13% (HR: 0.87; 95%CI, 0.80 - 0.95; p=0.002). When patients were divided based on use of VEGFR agents or an anti-VEGF monoclonal antibody, the reduction in the risk of death was 13% and 12%, respectively. If only treatmentnaïve patients are considered, we can confirm a significant reduction of 12% (HR=0.88; 95%CI, 0.79 - 0.97; p=0.010) in the risk of death. Our analysis reports a positive improvement of OS with the inhibition of the VEGF/VEGFR pathway in mRCC.

Original languageEnglish
Pages (from-to)164-170
Number of pages7
JournalCurrent Drug Targets
Volume16
Issue number2
Publication statusPublished - 2015

Fingerprint

Kidney Neoplasms
Vascular Endothelial Growth Factor A
Meta-Analysis
Renal Cell Carcinoma
Survival
Risk Reduction Behavior
Vascular Endothelial Growth Factor Receptor-1
PubMed
MEDLINE
Interferons
Libraries
Disease-Free Survival
Survival Rate
Monoclonal Antibodies
Placebos
Cells
Inhibition (Psychology)
Therapeutics
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer : a systematic review and meta-analysis. / Iacovelli, Roberto; Sternberg, Cora N.; Porta, Camillo; Verzoni, Elena; de Braud, Filippo; Escudier, Bernard; Procopio, Giuseppe.

In: Current Drug Targets, Vol. 16, No. 2, 2015, p. 164-170.

Research output: Contribution to journalArticle

@article{128a8a7d94c1492db959da3c8e2e6317,
title = "Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis",
abstract = "Despite the improvement in progression-free survival and response rates, none of the five anti- VEGF/VEGFR agents used for treatment of metastatic renal cell carcinoma (mRCC) reported a significant increase in patients' survival. This analysis aims to investigate their effect on overall survival (OS), performing a meta-analysis of the available studies. MEDLINE/PubMed and the Cochrane Library were searched for randomised phase III trials that compared anti-VEGF/VEGFR agents with controls as upfront treatment for mRCC. The search was restricted to phase III trials, and data extraction was conducted according to the PRISMA statement. Five randomised phase III trials were included for a total of 3,469 patients; among these, 1,801 received anti-VEGF/VEGFR agents and 1,668 were treated with a placebo or interferon-α. In the overall population, the reduction in the risk of death was 13{\%} (HR: 0.87; 95{\%}CI, 0.80 - 0.95; p=0.002). When patients were divided based on use of VEGFR agents or an anti-VEGF monoclonal antibody, the reduction in the risk of death was 13{\%} and 12{\%}, respectively. If only treatmentna{\"i}ve patients are considered, we can confirm a significant reduction of 12{\%} (HR=0.88; 95{\%}CI, 0.79 - 0.97; p=0.010) in the risk of death. Our analysis reports a positive improvement of OS with the inhibition of the VEGF/VEGFR pathway in mRCC.",
author = "Roberto Iacovelli and Sternberg, {Cora N.} and Camillo Porta and Elena Verzoni and {de Braud}, Filippo and Bernard Escudier and Giuseppe Procopio",
year = "2015",
language = "English",
volume = "16",
pages = "164--170",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer

T2 - a systematic review and meta-analysis

AU - Iacovelli, Roberto

AU - Sternberg, Cora N.

AU - Porta, Camillo

AU - Verzoni, Elena

AU - de Braud, Filippo

AU - Escudier, Bernard

AU - Procopio, Giuseppe

PY - 2015

Y1 - 2015

N2 - Despite the improvement in progression-free survival and response rates, none of the five anti- VEGF/VEGFR agents used for treatment of metastatic renal cell carcinoma (mRCC) reported a significant increase in patients' survival. This analysis aims to investigate their effect on overall survival (OS), performing a meta-analysis of the available studies. MEDLINE/PubMed and the Cochrane Library were searched for randomised phase III trials that compared anti-VEGF/VEGFR agents with controls as upfront treatment for mRCC. The search was restricted to phase III trials, and data extraction was conducted according to the PRISMA statement. Five randomised phase III trials were included for a total of 3,469 patients; among these, 1,801 received anti-VEGF/VEGFR agents and 1,668 were treated with a placebo or interferon-α. In the overall population, the reduction in the risk of death was 13% (HR: 0.87; 95%CI, 0.80 - 0.95; p=0.002). When patients were divided based on use of VEGFR agents or an anti-VEGF monoclonal antibody, the reduction in the risk of death was 13% and 12%, respectively. If only treatmentnaïve patients are considered, we can confirm a significant reduction of 12% (HR=0.88; 95%CI, 0.79 - 0.97; p=0.010) in the risk of death. Our analysis reports a positive improvement of OS with the inhibition of the VEGF/VEGFR pathway in mRCC.

AB - Despite the improvement in progression-free survival and response rates, none of the five anti- VEGF/VEGFR agents used for treatment of metastatic renal cell carcinoma (mRCC) reported a significant increase in patients' survival. This analysis aims to investigate their effect on overall survival (OS), performing a meta-analysis of the available studies. MEDLINE/PubMed and the Cochrane Library were searched for randomised phase III trials that compared anti-VEGF/VEGFR agents with controls as upfront treatment for mRCC. The search was restricted to phase III trials, and data extraction was conducted according to the PRISMA statement. Five randomised phase III trials were included for a total of 3,469 patients; among these, 1,801 received anti-VEGF/VEGFR agents and 1,668 were treated with a placebo or interferon-α. In the overall population, the reduction in the risk of death was 13% (HR: 0.87; 95%CI, 0.80 - 0.95; p=0.002). When patients were divided based on use of VEGFR agents or an anti-VEGF monoclonal antibody, the reduction in the risk of death was 13% and 12%, respectively. If only treatmentnaïve patients are considered, we can confirm a significant reduction of 12% (HR=0.88; 95%CI, 0.79 - 0.97; p=0.010) in the risk of death. Our analysis reports a positive improvement of OS with the inhibition of the VEGF/VEGFR pathway in mRCC.

UR - http://www.scopus.com/inward/record.url?scp=84946206105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946206105&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 164

EP - 170

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 2

ER -